Castle Biosciences Announces It Will Present Research Aimed At Enhancing The Clinical Management Of Patients With Cutaneous Melanoma And Uveal Melanoma At The 2025 American Society Of Clinical Oncology Annual Meeting

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients with cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30-June 3, 2025, in Chicago. This includes the latest findings from Castle's ongoing collaboration with the National Cancer Institute's Surveillance, Epidemiology and End Results (NCI's SEER) Program Registries affirming the significant, independent risk stratification provided by DecisionDx-Melanoma in an expanded, real-world cohort of more than 13,500 patients who received the test as part of their melanoma care.

"Management decisions for melanoma patients, such as referrals for sentinel lymph node biopsy and surveillance intensity, are guided by a patient's risk of dying from their disease," said Merve Hasanov, M.D., oncologist and director of the division of medical oncology at The Ohio State University Comprehensive Cancer Center in Columbus, Ohio. "The findings being presented at ASCO demonstrate that the DecisionDx-Melanoma test can provide more precise mortality risk predictions based on a patient's unique tumor biology and can improve upon the population-based risk assessment provided by American Joint Committee on Cancer (AJCC) staging. This can, in turn, help clinicians tailor treatment approaches to individual patient needs."

Castle's presentations at ASCO will take place during the Melanoma/Skin Cancers poster session on Sunday, June 1, from 9 a.m. to 12 p.m. Central time in Hall A – Posters and Exhibits.